Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.46 USD | -1.84% | +11.87% | +44.49% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Financials (USD)
Sales 2024 * | 9.6M | Sales 2025 * | 3.2M | Capitalization | 927M |
---|---|---|---|---|---|
Net income 2024 * | -104M | Net income 2025 * | -144M | EV / Sales 2024 * | 96.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 290 x |
P/E ratio 2024 * |
-8.56
x | P/E ratio 2025 * |
-6.88
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.97% |
1 day | -1.84% | ||
1 week | +11.87% | ||
Current month | +9.96% | ||
1 month | -23.69% | ||
3 months | -33.10% | ||
6 months | +76.08% | ||
Current year | +44.49% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 15.46 | -1.84% | 492,431 |
24-05-03 | 15.75 | +5.21% | 729,276 |
24-05-02 | 14.97 | +1.91% | 817,949 |
24-05-01 | 14.69 | +4.48% | 805,736 |
24-04-30 | 14.06 | +1.74% | 1,541,409 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.49% | 944M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- IMNM Stock